SUGAR trial @TCTMD
Cre8 EVO stent (70-80 microm) vs Zotarolimus DES stent
Study population: Patients with diabetics
Outcome target lesion failure (TLF) at 1 year
Design - non-inferiority trial
Procedural characteristics
between Cre8 EVO vs Resolute
anti platelets
Ok lets not get this wrong
This one met non-inferiority criteria for risk of TLF at one year
Is this correct? @SVRaoMD 😁
This may be helpful recap
Re: where the confidence interval is in relation to the null (1) and non-inferiority margin
In Sugar trial, they actually established superiority of Ceo8 EVO stent over Resolute
Which is basically choice A below
Correct me if I am wrong, @SVRaoMD
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.